HTGC
Hercules Capital, Inc. NYSE Listed Jun 9, 2005$16.44
Mkt Cap $3.0B
52w Low $13.70
45.9% of range
52w High $19.67
50d MA $14.99
200d MA $17.53
P/E (TTM)
8.6x
EV/EBITDA
15.5x
P/B
1.3x
Debt/Equity
1.0x
ROE
15.3%
P/FCF
-8.0x
RSI (14)
—
ATR (14)
—
Beta
0.78
50d MA
$14.99
200d MA
$17.53
Avg Volume
2.9M
About
Hercules Capital, Inc. is a business development company. The firm specializing in providing venture debt, debt, senior secured loans, and growth capital to privately held venture capital-backed companies at all stages of development from startups, to expansion stage including select publicly listed companies and select special opportunity lower middle market companies that require additional capi…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 0.47 | 0.48 | +2.1% | 16.57 | +2.3% | -0.8% | — | — | — | — | — |
| Feb 12, 2026 | AMC | 0.48 | 0.48 | +0.0% | 16.60 | -3.3% | -6.1% | -4.6% | -3.9% | -5.7% | -7.0% | — |
| Oct 30, 2025 | AMC | 0.48 | 0.49 | +2.1% | 17.59 | -0.5% | +1.9% | +1.3% | +2.2% | +2.8% | +1.1% | — |
| Jul 31, 2025 | AMC | 0.47 | 0.50 | +6.4% | 18.76 | +1.3% | +2.1% | +3.2% | +3.9% | +4.1% | +3.0% | — |
| May 1, 2025 | AMC | 0.46 | 0.45 | -2.2% | 17.81 | -1.3% | -0.9% | -1.9% | -1.9% | -3.0% | -1.2% | — |
| Feb 13, 2025 | AMC | 0.51 | 0.49 | -3.9% | 21.05 | -2.6% | +1.0% | +3.1% | +4.5% | +3.1% | +2.0% | — |
| Oct 30, 2024 | AMC | 0.51 | 0.51 | +0.0% | 19.90 | -0.5% | -0.7% | -3.4% | -3.9% | -3.9% | -0.6% | — |
| Aug 1, 2024 | AMC | 0.51 | 0.51 | +0.0% | 21.31 | -2.8% | -11.7% | -16.9% | -13.5% | -15.0% | -13.5% | — |
| May 2, 2024 | AMC | 0.50 | 0.50 | +0.0% | 19.30 | +0.6% | +0.7% | +2.0% | +2.4% | +2.1% | +2.9% | — |
| Feb 15, 2024 | AMC | 0.50 | 0.56 | +12.0% | 17.74 | +1.5% | +4.8% | +4.1% | +4.0% | +5.5% | +5.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Citizens | Maintains | Market Outperform → Market Outperform | — | $15.67 | $15.85 | +1.1% | +0.9% | -2.0% | -1.0% | -1.2% | -0.1% |
| Apr 16 | Keefe, Bruyette & Woods | Maintains | Outperform → Outperform | — | $15.68 | $15.74 | +0.4% | -0.3% | +1.8% | +1.5% | -0.1% | +0.8% |
| Apr 7 | Piper Sandler | Maintains | Neutral → Neutral | — | $15.18 | $15.10 | -0.5% | -0.4% | -1.3% | -2.9% | -1.5% | +0.7% |
| Mar 13 | UBS | Maintains | Neutral → Neutral | — | $14.04 | $14.13 | +0.6% | +0.0% | +0.1% | +3.3% | +3.0% | +2.7% |
| Feb 13 | Wells Fargo | Maintains | Overweight → Overweight | — | $16.60 | $16.06 | -3.3% | -6.1% | -4.6% | -3.9% | -5.7% | -7.0% |
| Feb 13 | Piper Sandler | Downgrade | Overweight → Neutral | — | $16.60 | $16.06 | -3.3% | -6.1% | -4.6% | -3.9% | -5.7% | -7.0% |
| Feb 13 | Keefe, Bruyette & Woods | Maintains | Outperform → Outperform | — | $16.60 | $16.06 | -3.3% | -6.1% | -4.6% | -3.9% | -5.7% | -7.0% |
| Nov 4 | Compass Point | Upgrade | Neutral → Buy | — | $17.81 | $17.87 | +0.3% | +0.9% | +1.5% | -0.2% | +1.1% | +0.2% |
| Oct 14 | UBS | Maintains | Neutral → Neutral | — | $17.13 | $16.95 | -1.1% | +1.7% | +1.5% | +0.2% | +0.8% | +2.1% |
| Oct 9 | Piper Sandler | Maintains | Overweight → Overweight | — | $17.71 | $17.60 | -0.6% | -3.7% | -5.7% | -3.3% | -1.6% | -1.8% |
Recent Filings
8-K
Hercules Capital, Inc. -- 8-K Filing
Hercules Capital appointed Olson as Interim Chief Financial Officer, bringing finance leadership experience and CPA credentials to guide the company's financial operations.
May 4
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary describes only technical XBRL metadata and form structure rather than actual company events or financial disclosures that would impact stock valuations.
Apr 1
8-K
enGene Therapeutics Inc. -- 8-K Filing
enGene Therapeutics announced Q1 2026 results and expects to present updated data from its LEGEND trial for bladder cancer treatment at an upcoming spring medical conference.
Mar 9
8-K · 5.02
!!! Very High
MoonLake Immunotherapeutics Class A -- 8-K 5.02: Executive Change
MoonLake Immunotherapeutics (MLTX) appointed an interim chair and two new independent directors while Simon Sturge resigned, signaling potential governance restructuring that investors should monitor for strategic implications.
Feb 23
8-K
Hercules Capital, Inc. -- 8-K Filing
I cannot provide a meaningful analysis from this filing summary, as it appears to contain only signature and administrative sections without disclosing a specific corporate event or financial transaction affecting investor interests.
Feb 12
8-K · 1.01
! Medium
Hercules Capital, Inc. -- 8-K 1.01: Underwriting / Securities
Hercules Capital established a tenth supplemental indenture with Goldman Sachs, likely modifying debt terms or issuing new securities to strengthen its capital structure and financing flexibility.
Feb 10
8-K · 1.01
!! High
Maze Therapeutics, Inc. -- 8-K 1.01: Material Agreement
Maze Therapeutics secured $40 million in initial term loan funding from Hercules Capital, providing capital for operations and development while obligating the company to repay debt.
Feb 4
8-K · 8.01
!! High
Hercules Capital, Inc. -- 8-K 8.01: Material Event / Announcement
Hercules Capital reported approximately $20 million in realized gains for Q4 2025, with NAV per share rising $0.05 to $0.11 as of September 30, 2025.
Feb 3
8-K · 1.01
!! High
Replimune Group, Inc. -- 8-K 1.01: Material Agreement
Replimune secured an additional $30 million in funding from Hercules Capital through a loan amendment, providing financial flexibility for the biotech company's clinical development programs.
Feb 3
Data updated apr 25, 2026 2:13pm
· Source: massive.com